중합효소 연쇄 반응(PCR) 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 제품 유형별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Polymerase Chain Reaction Market Summary

The global polymerase chain reaction market size was estimated at USD 15.19 billion in 2025 and is projected to reach USD 24.78 billion by 2033, growing at a CAGR of 6.36% from 2026 to 2033. The market growth is driven by the increasing demand for rapid and accurate molecular diagnostics across clinical, research, and forensic applications.

PCR technology enables the amplification of small segments of DNA or RNA, allowing for precise detection of pathogens, genetic mutations, and biomarkers.

The growing prevalence of infectious diseases, genetic disorders, and cancer has accelerated the adoption of PCR-based testing in hospitals, diagnostic laboratories, and research institutes. In addition, the expansion of molecular diagnostics and personalized medicine has strengthened the role of PCR technologies in modern healthcare systems.However, some of the key factors, such as the rising application of polymerase chain reaction (PCR) in research and forensic laboratories and increasing demand for advanced diagnostics, are anticipated to increase the demand for polymerase chain reaction tests. In addition, the launch of novel technologies and the increasing number of contract research organizations are likely to drive demand for PCR tests forward during the forecast period.

The increase in the prevalence of chronic and infectious diseases and genetic disorders is expected to boost the demand during the forecast period. According to the CDC, chronic diseases such as cancer and diabetes, and chronic kidney and respiratory diseases such as asthma, are responsible for 7 in 10 deaths in the U.S. each year. Furthermore, the number of patients suffering from congenital heart disease is increasing, requiring medical professionals to look for molecular diagnostic tools for accurate diagnoses. According to the CDC, congenital heart defects are the most common birth defects in the U.S., affecting approximately 1% of births every year. Thus, the increasing prevalence of diseases is increasing the demand for novel molecular diagnostic tests during the forecast period.

The rising demand for prenatal genetic testing procedures owing to growing awareness regarding genetic disorders, such as cystic fibrosis, hemophilia, and thalassemia, is expected to propel the industry growth. In the early stages of pregnancy, fetal DNA present in the mother's blood or the amniotic fluid can be analyzed to detect genetic defects before birth using qPCR and dPCR techniques. Possible genetic aberrations and fetuses with defective genes can then be treated during early pregnancy.

Technological advancements such as real-time PCR (qPCR), digital PCR (dPCR), and multiplex PCR have improved sensitivity, specificity, and throughput in diagnostic testing. The COVID-19 pandemic significantly boosted global PCR testing infrastructure, leading to increased investments in automated systems and high-throughput platforms. Major companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN, F. Hoffmann-La Roche, and Agilent Technologies continue to develop advanced PCR instruments, reagents, and consumables to support clinical diagnostics, pharmaceutical research, and biotechnology applications. The growing focus on early disease detection, expanding genomic research, and increasing government funding for molecular biology research are expected to further drive market growth.

Global Polymerase Chain Reaction Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global polymerase chain reaction market report based on the type, product, application, and region:

• Type Method Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Conventional PCR
• Others
• Product Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Consumables & Reagents
• Instruments
• Software & Services
• Application Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Medical
  • Clinical
  • Pathology Testing
  • Oncology Testing
  • Blood Screening
  • Others
  • Research
  • Forensics and Others
• Non-medical
  • Food
  • Others
• Regional Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE

Table of Contents

Chapter 1. Polymerase Chain Reaction Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type Segment
    • 1.1.1.2. Product Segment
    • 1.1.1.3. Application Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Polymerase Chain Reaction Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Type Snapshot
• 2.3. Product Snapshot
• 2.4. Application Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Polymerase Chain Reaction Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
• 3.5. Market Restraint Analysis
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Polymerase Chain Reaction Market: Type Estimates & Trend Analysis

• 4.1. Global Polymerase Chain Reaction Market: Type Dashboard
• 4.2. Global Polymerase Chain Reaction Market: Type Movement Analysis
• 4.3. Global Polymerase Chain Reaction Market by brand, Revenue
• 4.4. Conventional PCR
  • 4.4.1. Conventional PCR market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.5. Others
  • 4.5.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Polymerase Chain Reaction Market: Product Estimates & Trend Analysis

• 5.1. Global Polymerase Chain Reaction Market: Product Dashboard
• 5.2. Global Polymerase Chain Reaction Market: Product Movement Analysis
• 5.3. Global Polymerase Chain Reaction Market by Product, Revenue
• 5.4. Consumables & Reagents
  • 5.4.1. Consumables & Reagents market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.5. Instruments
  • 5.5.1. Instruments market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Software & Services
  • 5.6.1. Software & Services market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Polymerase Chain Reaction Market: Application Estimates & Trend Analysis

• 6.1. Global Polymerase Chain Reaction Market: Application Dashboard
• 6.2. Global Polymerase Chain Reaction Market: Application Movement Analysis
• 6.3. Global Polymerase Chain Reaction Market by Application, Revenue
• 6.4. Medical
  • 6.4.1. Medical market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.4.2. Clinical
    • 6.4.2.1. Clinical market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.4.2.2. Pathology Testing
      • 6.4.2.2.1. Pathology Testing market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.4.2.3. Oncology Testing
      • 6.4.2.3.1. Oncology Testing market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.4.2.4. Blood Screening
      • 6.4.2.4.1. Blood Screening market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.4.2.5. Others
      • 6.4.2.5.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.4.3. Research
    • 6.4.3.1. Research market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.4.4. Forensics and Others
    • 6.4.4.1. Forensics and Others market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.5. Non-Medical
  • 6.5.1. Non-Medical market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5.2. Food
    • 6.5.2.1. Food market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5.3. Others
    • 6.5.3.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Polymerase Chain Reaction Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Thermo Fisher Scientific Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Danaher
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Abbott
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Bio-Rad Laboratories, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Agilent Technologies, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. QIAGEN
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. F. Hoffmann-La Roche Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Stilla
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Standard BioTools
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Microsynth AG
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives